ストックスクリーナーアプリを入手
0.403
4.05%
-0.017
プレマーケット:
.40
-0.003
-0.74%
前日終値:
$0.42
開ける：
$0.4074
24時間の取引高:
398.66K
Relative Volume:
0.03
時価総額：
$46.38M
収益：
$20.27M
当期純損益:
$-63.80M
株価収益率:
-0.2651
EPS:
-1.52
ネットキャッシュフロー:
$-68.35M
1週間 パフォーマンス:
-0.84%
1か月 パフォーマンス:
+126.79%
6か月 パフォーマンス:
-23.69%
1年 パフォーマンス:
-71.01%
1日の値動き範囲:
$0.4001
$0.4267
1週間の範囲:
$0.369
$0.4399
52週間の値動き範囲:
$0.1417
$1.38
Carisma Therapeutics Inc Stock (CARM) Company Profile
名前
Carisma Therapeutics Inc
セクター
電話
(267) 491-6422
住所
3675 MARKET STREET, PHILADELPHIA
CARM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CARM
Carisma Therapeutics Inc
|
0.403 | 46.38M | 20.27M | -63.80M | -68.35M | -1.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Carisma Therapeutics Inc Stock (CARM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-12 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-12-10 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-04-11 | 開始されました | BTIG Research | Buy |
| 2023-10-03 | 開始されました | CapitalOne | Overweight |
| 2023-07-06 | 開始されました | Evercore ISI | Outperform |
| 2023-05-31 | アップグレード | Jefferies | Hold → Buy |
| 2023-05-24 | 開始されました | H.C. Wainwright | Buy |
| 2023-04-14 | 開始されました | Robert W. Baird | Outperform |
すべてを表示
Carisma Therapeutics Inc (CARM) 最新ニュース
Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Sold by Millennium Management LLC - Defense World
Carisma Therapeutics, Inc. (NASDAQ:CARM) Stock Position Decreased by Millennium Management LLC - Defense World
Millennium Management LLC Takes Position in Marker Therapeutics, Inc. (NASDAQ:MRKR) - Defense World
Carisma Therapeutics Secures Nasdaq Listing Approval - TipRanks
Is the 250% Carisma Therapeutics Stock (CARM) Surge a Sucker’s Rally? - The Globe and Mail
Dow Rises Over 50 Points; US Inflation Rate Increases In May - Benzinga
Carisma Therapeutics Stock (CARM) Retreats 35% After a Massive Rally - TipRanks
US Stocks Mixed; JM Smucker Shares Plunge After Q4 Results - Benzinga
Pre-market Movers: EVGN, WINT, CARM, UNCY... - RTTNews
Why Casey's General Stores Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket - Benzinga
Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Average Recommendation of “Hold” by Brokerages - Defense World
Carisma Therapeutics Reports Q1 2025 Financial Results - TipRanks
Carisma Therapeutics Inc (CARM): An Important Analyst Insights - Stocksregister
Layoff Tracker: Eikon Cuts Workforce by 15%, Citing ‘External Forces’ - BioSpace
Carisma Therapeutics Inc (NASDAQ: CARM) Stock Sentiment: What’s Wall Street Saying? - Stocksregister
Carisma Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Pre-market Movers: LUCY, ALUR, PLRZ, AXDX... - RTTNews
Financial Metrics Unveiled: Carisma Therapeutics Inc (CARM)’s Key Ratios in the Spotlight - DWinneX
Carisma Therapeutics Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
Caribou cuts 32% of staff, further purges pipeline to focus on 2 oncology CAR-T prospects - Fierce Biotech
Carisma Therapeutics to Present at Upcoming Conferences - Seeking Alpha
Biopharma restructurings reflect strategy of short-term pain for long-term gains - BioWorld MedTech
Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Average Rating of “Hold” by Analysts - Defense World
Sagimet Biosciences (NASDAQ:SGMT) and Carisma Therapeutics (NASDAQ:CARM) Head-To-Head Review - Defense World
Philly weekly roundup: Carisma Therapeutics layoffs; PPA's AI ticketing; HiveBio's first cohort - Technical.ly
Carisma Therapeutics Inc’s Market Journey: Closing Weak at 0.19, Down -0.26 - DWinneX
CARISMA THERAPEUTICS Earnings Preview: Recent $CARM Insider Trading, Hedge Fund Activity, and More - Nasdaq
Carisma Therapeutics Focuses on Strategic Alternatives Amid Revised Operating Plan - MSN
Philly’s Carisma Therapeutics slashed its workforce to 6 from 46 for sale or wind down - MSN
Carisma Therapeutics Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Carisma Therapeutics (NASDAQ:CARM) Price Target Lowered to $1.00 at D. Boral Capital - Defense World
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Carisma Therapeutics to Present at AASLD 2024 on Liver Fibrosis Treatment - MSN
Carisma winds down operations, lays off 95% of remaining staff - Fierce Biotech
Penn spinout Carisma Therapeutics lays off 84% of its staff, explores possible sale - The Business Journals
Carisma Therapeutics Provides Corporate Updates - Citizen Tribune
Carisma Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Carisma Therapeutics Board Approves Revised Operating Plan; Reduces Workforce - MarketScreener
Carisma Therapeutics Inc. SEC 10-K Report - TradingView
Carisma Therapeutics Explores Sale Options as Company Halts R&D Programs - Stock Titan
Carisma Therapeutics (CARM) to Release Earnings on Monday - The AM Reporter
Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Business And Shares Still Trailing The Industry - simplywall.st
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors - Business Wire
Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Consensus Rating of “Hold” from Analysts - Defense World
Carisma Therapeutics Inc (CARM) 財務データ
収益
当期純利益
現金流量
EPS
0.68%
0.50%
大文字化:
|
ボリューム (24 時間):